Navigation Links
ETHICON Introduces New Product Enhancement and Packaging for BIOPATCH(R) to Improve Ease of Application for Patients with Catheters
Date:8/11/2009

SOMERVILLE, N.J., Aug. 11 /PRNewswire/ -- ETHICON, Inc., a Johnson & Johnson Company, today announced that BIOPATCH((R)) Protective Disk with CHG (chlorhexidine gluconate) will include new design elements and updated packaging to make it easier for surgeons, nurses and other healthcare providers to apply the product correctly around catheters to reduce the risk of catheter-related bloodstream infections (CRBSIs). Distribution of BIOPATCH((R)) with the enhanced design and packaging began on August 10, 2009 and the product will be available nationwide by mid-August.

BIOPATCH((R)) is placed directly on the skin at the point of catheter insertion and provides seven days of continuous active antisepsis. In a clinical study, the use of BIOPATCH((R)) was associated with a 76% reduction in CRBSI(1). Published practice standards as outlined by key healthcare organizations - SHEA, ISDA, AHA, APIC and the Joint Commission - include using a "chlorhexidine-containing sponge dressing" as a strategy for reducing CRBSIs. BIOPATCH((R)) is the only product of its kind with an FDA-cleared indication to reduce CRBSI.

The enhanced design and packaging for BIOPATCH((R)) includes easy-to-follow instructions and clearly marked "up" arrows to signify correct application with respect to skin orientation of the product. This new design is intended to provide clear and immediate guidance on the application of BIOPATCH((R)) with each use. In addition, BIOPATCH((R)) packaging now features color-coded elements designed to instantly identify the size and center-hole diameter of the product.

"Proper application of a medical device is essential for maximizing efficacy," said Leigh Ann Bowe-Geddes, BS, RN, CRNI, a vascular access specialist at the University of Louisville Hospital in Louisville, KY. "The new design of BIOPATCH((R) )helps ensure that this technology is used properly, which helps protect patients in the fight against infection."

In the U.S., approximately 80,000 central venous CRBSIs are estimated to occur each year in ICU patients. CRBSIs are associated with extended hospital stays, requiring an estimated 9-12 additional days in hospital. According to the CDC, the cost of treating a CRBSI can range from $34,508 - $56,000. The average cost of the BIOPATCH((R)) product is approximately $6.

The safety and effectiveness of BIOPATCH((R)) have not been established for children less than 16 years of age. The protective disk is not to be used on premature infants or on patients with a known sensitivity to CHG.

BIOPATCH((R)) is marketed by ETHICON, Inc., a Johnson & Johnson company. ETHICON continues Johnson & Johnson's 100-year commitment to wound care today with innovative products for general surgery, wound management, women's health and urology, aesthetic medicine and wound closure. For more information about ETHICON visit www.ethicon.com.

(1) Timsit, J-F, et al. "Chlorhexidine-Impregnated Sponges and Less-Frequent Dressing Changes for Prevention of Catheter-Related Infections in Critically Ill Adults." JAMA, 2009;301(12):1231-1241.


'/>"/>
SOURCE ETHICON, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
2. ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business
3. ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners
4. Board-Certified Bariatric Surgeon, Trace Curry, MD Places First Next-Generation Ethicon Endo-Surgery REALIZE™ Adjustable Gastric Band-C in Ohio
5. ETHICON Launches the Latest Innovation in Hernia Repair Platform; PROCEED(TM) Ventral Patch (PVP(TM) Device)
6. Board-Certified Bariatric Surgeon, Trace Curry, MD Places First Next-Generation Ethicon Endo-Surgery REALIZE™ Adjustable Gastric Band-C in Ohio
7. FDA Grants Ethicon Endo-Surgery Approval of Its IDE Application to Commence Study of Notes Toolbox(TM)
8. Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages
9. NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones
10. Ethicon Endo-Surgery Holds Metabolic Surgery Scientific Forum Featuring Research By Top Scientists
11. Delta Dental of Illinois Introduces Smile Smart For Your Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... , ... BrightStar Care Marietta announced that it has received the 2017 Best ... is granted only to top-ranking home care providers, based on client satisfaction scores gathered ... care providers from across the country who have proven their ability to provide the ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... care industry, announces Chris Brandl as its New Guest Director. , Brandl ... to corporations throughout his career. He began his professional career at Omnium Worldwide, ...
(Date:2/27/2017)... Ohio (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your ... Life” to studying to become a nun. Now, she writes about God, when she isn’t ... “You Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... ... Research and Markets has announced the addition of the ... their offering. The global active pharmaceutical ingredients (API) ... by 2025. The rising prevalence of lifestyle-induced & age-related diseases and ... Advancements in recombinant molecular technologies and high capitalization for development of ...
(Date:2/28/2017)... Feb. 27, 2017  Titan Pharmaceuticals, Inc. (NASDAQ: ... treatment of select chronic diseases utilizing its ProNeura™ ... the U.S. Food & Drug Administration (FDA) has ... Investigational New Drug Application (IND) and has requested ... study pending submission of the requested information and ...
(Date:2/28/2017)... -- Medical robots market is projected to reach USD ... 2016, growing at a CAGR of 21.1% in the ... Read the full report: http://www.reportlinker.com/p04730562-summary/view-report.html ... advancements, increase in funding for medical robots research, issuance ... investments are the key factors driving the growth of ...
Breaking Medicine Technology: